Cargando…
Immune thrombotic thrombocytopenic purpura: Spotlight on long-term outcomes and survivorship
Advances in diagnosis and treatment have dramatically improved survival of acute immune thrombotic thrombocytopenic purpura (iTTP) and iTTP has evolved from an acute fatal condition to a chronic relapsing disorder. In addition to the risk of iTTP relapse, iTTP survivors are at risk of multiple adver...
Autores principales: | Selvakumar, Sruthi, Liu, Angela, Chaturvedi, Shruti |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011081/ https://www.ncbi.nlm.nih.gov/pubmed/36926315 http://dx.doi.org/10.3389/fmed.2023.1137019 |
Ejemplares similares
-
Thrombotic Thrombocytopenic Purpura After Ad6.COV2.S Vaccination
por: Ramanan, Sruthi, et al.
Publicado: (2022) -
Valacyclovir-Induced Thrombotic Thrombocytopenic Purpura
por: Bukhari, Sumera, et al.
Publicado: (2020) -
Caplacizumab use for immune thrombotic thrombocytopenic purpura: the Milan thrombotic thrombocytopenic purpura registry
por: Agosti, Pasquale, et al.
Publicado: (2023) -
Outcomes of Immune Thrombotic Thrombocytopenic Purpura (iTTP) With Upfront Cyclophosphamide vs. Rituximab
por: Abou-Ismail, Mouhamed Yazan, et al.
Publicado: (2020) -
Caplacizumab for immune thrombotic thrombocytopenic purpura: real-world multicenter data
por: Gavriilaki, Eleni, et al.
Publicado: (2023)